Literature DB >> 33440831

Mortality and Transfusion Requirements in COVID-19 Hospitalized Italian Patients According to Severity of the Disease.

Elvira Grandone1,2, Raffaele Pesavento3, Giovanni Tiscia1, Antonio De Laurenzo1, Davide Ceccato3, Maria Teresa Sartori3, Lucia Mirabella4, Gilda Cinnella4, Mario Mastroianno5, Lidia Dalfino6, Donatella Colaizzo1, Roberto Vettor3, Angelo Ostuni7, Maurizio Margaglione8.   

Abstract

There is paucity of data on the transfusion need and its impact on the overall mortality in patients with COVID-19. We explored mortality in hospitalized patients with COVID-19 who required transfusions. Information on clinical variables and in-hospital mortality were obtained from medical records of 422 patients admitted to medical wards or the Intensive Care Unit (ICU). In-hospital mortality occurred in 147 (34.8%) patients, 94 (63.9%) of whom were admitted to the ICU. The median fatalities age was 77 years (IQR 14). Overall, 100 patients (60 males) received transfusion during hospitalization. The overall mortality was significantly and independently associated with age, ICU admission, Chronic Kidney Disease (CKD), and the number of transfused Red Blood Cell (RBC) units. Specifically, CKD was associated with mortality in patients admitted to medical wards, whereas the number of transfused RBC units predicted mortality in those admitted to the ICU. Transfusion strongly interacted with the admission to ICU (OR: 9.9; 95% CI: 2.5-40.0). In patients with COVID-19, age is one of the strongest risk factors in predicting mortality independently of the disease's severity. CKD confers a higher risk of mortality in patients admitted to medical wards. In those admitted to the ICU, the more RBC units are transfused, the more mortality increases.

Entities:  

Keywords:  COVID-19; ICU; medical ward; mortality; transfusion

Year:  2021        PMID: 33440831     DOI: 10.3390/jcm10020242

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  1 in total

1.  Use of low-molecular weight heparin, transfusion and mortality in COVID-19 patients not requiring ventilation.

Authors:  Elvira Grandone; Giovanni Tiscia; Raffaele Pesavento; Antonio De Laurenzo; Davide Ceccato; Maria Teresa Sartori; Lucia Mirabella; Gilda Cinnella; Mario Mastroianno; Lidia Dalfino; Donatella Colaizzo; Roberto Vettor; Mariano Intrieri; Angelo Ostuni; Maurizio Margaglione
Journal:  J Thromb Thrombolysis       Date:  2021-04-12       Impact factor: 2.300

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.